Saskia Vosslamber

1.2k total citations
32 papers, 838 citations indexed

About

Saskia Vosslamber is a scholar working on Rheumatology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Saskia Vosslamber has authored 32 papers receiving a total of 838 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Rheumatology, 12 papers in Oncology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Saskia Vosslamber's work include Rheumatoid Arthritis Research and Therapies (19 papers), Systemic Lupus Erythematosus Research (15 papers) and Cytokine Signaling Pathways and Interactions (10 papers). Saskia Vosslamber is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (19 papers), Systemic Lupus Erythematosus Research (15 papers) and Cytokine Signaling Pathways and Interactions (10 papers). Saskia Vosslamber collaborates with scholars based in Netherlands, United States and Sweden. Saskia Vosslamber's co-authors include Cornelis L. Verweij, Michael T. Nurmohamed, Alexandre E. Voskuyl, Dirkjan van Schaardenburg, Willem F. Lems, Sander de Ridder, Joyce Lübbers, Ben A. C. Dijkmans, Hennie G. Raterman and John G. Wesseling and has published in prestigious journals such as PLoS ONE, Annals of the Rheumatic Diseases and Arthritis Research & Therapy.

In The Last Decade

Saskia Vosslamber

31 papers receiving 812 citations

Peers

Saskia Vosslamber
Yasuo Nagafuchi Japan
Nina Daha Netherlands
Consuelo Anzilotti United Kingdom
Audi Setiadi Canada
G. Cavet United States
Rekha Parmar United Kingdom
Gerrie Stoeken‐Rijsbergen Netherlands
Edward Flynn United Kingdom
Jeff Faint United Kingdom
Sang Taek Kim United States
Yasuo Nagafuchi Japan
Saskia Vosslamber
Citations per year, relative to Saskia Vosslamber Saskia Vosslamber (= 1×) peers Yasuo Nagafuchi

Countries citing papers authored by Saskia Vosslamber

Since Specialization
Citations

This map shows the geographic impact of Saskia Vosslamber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saskia Vosslamber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saskia Vosslamber more than expected).

Fields of papers citing papers by Saskia Vosslamber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saskia Vosslamber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saskia Vosslamber. The network helps show where Saskia Vosslamber may publish in the future.

Co-authorship network of co-authors of Saskia Vosslamber

This figure shows the co-authorship network connecting the top 25 collaborators of Saskia Vosslamber. A scholar is included among the top collaborators of Saskia Vosslamber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saskia Vosslamber. Saskia Vosslamber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sellam, Jérémie, Rabia Agca, Saskia Vosslamber, et al.. (2017). A multi-parameter response prediction model for rituximab in rheumatoid arthritis. Joint Bone Spine. 85(2). 219–226. 17 indexed citations
2.
Sellam, Jérémie, Rabia Agca, Saskia Vosslamber, et al.. (2017). 07.01 A multi-parameter response prediction model for rituximab in rheumatoid arthritis. Annals of the Rheumatic Diseases. 76. A67–A67. 1 indexed citations
3.
Lübbers, Joyce, Samina A. Turk, Saskia Vosslamber, et al.. (2016). The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytes. Arthritis Research & Therapy. 18(1). 165–165. 27 indexed citations
4.
Lübbers, Joyce, Marian H. van Beers-Tas, Saskia Vosslamber, et al.. (2016). Changes in peripheral blood lymphocyte subsets during arthritis development in arthralgia patients. Arthritis Research & Therapy. 18(1). 205–205. 33 indexed citations
5.
Vosslamber, Saskia, Sander de Ridder, John G. Wesseling, et al.. (2016). Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases. Arthritis Research & Therapy. 18(1). 49–49. 28 indexed citations
6.
Ridder, Sander de, et al.. (2016). Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters. Arthritis Research & Therapy. 18(1). 290–290. 18 indexed citations
7.
Sluijter, Berbel J.R., Mari F.C.M. van den Hout, Bas D. Koster, et al.. (2015). Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141+ Dendritic Cells and Enhanced Cross-Presentation. Cancer Immunology Research. 3(5). 495–505. 50 indexed citations
8.
Vosslamber, Saskia, Gertjan Wolbink, Michael T. Nurmohamed, et al.. (2015). Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. Arthritis Research & Therapy. 17(1). 78–78. 41 indexed citations
9.
Vosslamber, Saskia, Wilco de Jager, Hennie G. Raterman, et al.. (2014). A1.7 Serum cytokine changes in rituximab-treated rheumatoid arthritis patients. Annals of the Rheumatic Diseases. 73. A3–A3. 1 indexed citations
10.
Lübbers, Joyce, Mikael Brink, Lotte A van de Stadt, et al.. (2013). The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Annals of the Rheumatic Diseases. 72(5). 776–780. 120 indexed citations
11.
Tossberg, John T., Philip S. Crooke, Melodie A. Henderson, et al.. (2013). Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis. PubMed. 3(1). 18–18. 9 indexed citations
12.
Lübbers, Joyce, et al.. (2013). FRI0101 The value of gene signatures in the diagnosis of pre-clinical ra. Annals of the Rheumatic Diseases. 72. A404–A404. 1 indexed citations
13.
Vosslamber, Saskia, et al.. (2013). A10.20 On the Origin of the Type I Interferon Activity in Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 72. A79–A79. 1 indexed citations
14.
Raterman, Hennie G., Saskia Vosslamber, Sander de Ridder, et al.. (2012). The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Research & Therapy. 14(2). R95–R95. 143 indexed citations
15.
Jansen, Gerrit, et al.. (2012). Gene expression profiling of folate pathway related genes in methotrexate naïve- and methotrexate-treated rheumatoid arthritis patients. Annals of the Rheumatic Diseases. 71. A53–A53. 2 indexed citations
16.
Vosslamber, Saskia, Hennie G. Raterman, Tineke C. T. M. van der Pouw Kraan, et al.. (2011). Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Annals of the Rheumatic Diseases. 70(6). 1153–1159. 43 indexed citations
17.
Tossberg, John T., Philip S. Crooke, Melodie A. Henderson, et al.. (2011). Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis. Genes and Immunity. 13(2). 146–154. 18 indexed citations
18.
Verweij, Cornelis L. & Saskia Vosslamber. (2011). Combining DNA-microarray data in systemic lupus erythematosus. Genome Medicine. 3(5). 30–30. 2 indexed citations
19.
Vosslamber, Saskia, L.F. van der Voort, Roel Heijmans, et al.. (2011). Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis. Genes and Immunity. 12(6). 466–472. 25 indexed citations
20.
Baarsen, Lisa G. M. van, Saskia Vosslamber, Marianne Tijssen, et al.. (2008). Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients. PLoS ONE. 3(4). e1927–e1927. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasuo Nagafuchi Breakdown of academic impact, for papers by Nina Daha Breakdown of academic impact, for papers by Consuelo Anzilotti Breakdown of academic impact, for papers by Audi Setiadi Breakdown of academic impact, for papers by G. Cavet Breakdown of academic impact, for papers by Rekha Parmar Breakdown of academic impact, for papers by Gerrie Stoeken‐Rijsbergen Breakdown of academic impact, for papers by Edward Flynn Breakdown of academic impact, for papers by Jeff Faint Breakdown of academic impact, for papers by Sang Taek Kim
Rankless by CCL
2026